9327 Abnormal Presentation of Myoedema and Pseudohypertrophy in Hypothyroidism

• Published in: Journal of the Endocrine Society 2024-10, Vol.8 (Supplement_1)
• Main Authors: Sperry, Bailey, Horani, Mohamad Hosam
• Format: Article
• Language: English
• Subjects: Abstract
• ISSN: 2472-1972; 2472-1972
• DOI: 10.1210/jendso/bvae163.1885

Abstract Disclosure: B. Sperry: None. M.H. Horani: None. Atypical presentations of hypothyroidism are dramatically under researched and studied in the male population. Signs and symptoms of myoedema and pseudohypertrophy, which can be classified as overt signs of hypothyroidism, should be in the differential for hypothyroidism to decrease the delay in diagnosis and patient care. Hypothyroidism is a common pathological process that has been well studied in the endocrinology society. By definition, it is the abnormally low production of the thyroid gland, resulting in slowing of growth and mental development in children and metabolic changes in adults (1). However, in a community survey, only 0.1-2 percent of patients present with overt signs of hypothyroidism; of that, only 1/1000 males presented with overt signs whereas females were at a range of 14/1000 to 19/1000 when including all scenarios and cases [1]. It should be made apparent that although autoimmune disorders are more common in females, the male population has been dramatically overlooked which poses a risk to patient care and proper diagnosis and treatment. Although it may be difficult to diagnose hypothyroidism with only physical signs and symptoms of myoedema and pseudo-hypertrophy, these are key clinical features of Hoffman’s syndrome; which is well-known to be associated with hypothyroidism. Rhabdomyolysis can be a complication secondary to myoedema and further diagnostic studies should be obtained to ensure the diagnosis of hypothyroidism is not missed. I present a case of a 32-year-old male who was not properly diagnosed with hypothyroidism until after the third hospitalization, despite showing overt signs and symptoms of hypothyroidism which put him at risk of end-organ damage. Presentation: 6/3/2024